Dose-Dependent, Therapeutic Potential of Angiotensin-(1–7) for the Treatment of Pulmonary Arterial Hypertension

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pulmonary Circulation

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/683696PMID 26697172PMCID PMC4671739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression

  2015cited by this paper
• An Update of the Role of Renin Angiotensin in Cardiovascular Homeostasis

  2015cited by this paper
• Angiotensin‐(1‐7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation

  2015cited by this paper
• Chronic Treatment with Ang-(1-7) Reverses Abnormal Reactivity in the Corpus Cavernosum and Normalizes Diabetes-Induced Changes in the Protein Levels of ACE, ACE2, ROCK1, ROCK2 and Omega-Hydroxylase in a Rat Model of Type 1 Diabetes

  2014cited by this paper
• ACE and ACE2 in inflammation: a tale of two enzymes.

  2014cited by this paper
• [Updated clinical classification of pulmonary hypertension].

  2014cited by this paper
• ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis

  2013cited by this paper
• Angiotensin‐(1–7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2‐ and NF‐κB‐dependent pathways

  2012influential reference
• New therapeutic pathways in the RAS

  2012cited by this paper
• The Effect of the Thioether-Bridged, Stabilized Angiotensin-(1–7) Analogue Cyclic Ang-(1–7) on Cardiac Remodeling and Endothelial Function in Rats with Myocardial Infarction

  2011cited by this paper
• Ang-(1-7) might prevent the development of monocrotaline induced pulmonary arterial hypertension in rats.

  2011influential reference
• Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension

  2010cited by this paper
• The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.

  2010influential reference
• Different Effects of Angiotensin II and Angiotensin-(1-7) on Vascular Smooth Muscle Cell Proliferation and Migration

  2010cited by this paper
• Mast cells promote lung vascular remodelling in pulmonary hypertension

  2010cited by this paper
• Oral and pulmonary delivery of thioether-bridged angiotensin-(1-7).

  2010cited by this paper
• Angiotensin-(1-7) with Thioether Bridge: An Angiotensin-Converting Enzyme-Resistant, Potent Angiotensin-(1-7) Analog

  2009cited by this paper
• Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.

  2009cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation

  2009cited by this paper
• Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease*

  2009cited by this paper
• Therapeutic targets in pulmonary arterial hypertension.

  2009cited by this paper
• Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

  2008cited by this paper
• Inhaled milrinone attenuates experimental acute lung injury

  2008cited by this paper
• Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2

  2008cited by this paper
• Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent Pathways

  2007influential reference
• Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction.

  2007influential reference
• Cardiovascular-Renal Mechanisms in Health and Disease Prevention of angiotensin II-induced cardiac remodeling by angiotensin-( 1 – 7 )

  2007cited by this paper
• Ambrisentan therapy for pulmonary arterial hypertension.

  2005influential reference
• The endothelin system in pulmonary arterial hypertension.

  2004cited by this paper
• Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats.

  2004cited by this paper
• Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas

  2003cited by this paper
• Angiotensin-(1-7)–Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells

  2001cited by this paper
• Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension.

  2000influential reference
• State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle.

  1999cited by this paper
• Antiproliferative Actions of Angiotensin-(1-7) in Vascular Smooth Muscle

  1999cited by this paper
• Converting enzyme determines plasma clearance of angiotensin-(1-7).

  1998cited by this paper

• Angiotensin 1–7 increases cardiac tolerance to ischemia/reperfusion and mitigates adverse remodeling of the heart—The signaling mechanism

  2024cites this paper
• Ang-(1-7) and ET-1 Interplay Through Mas and ETB Receptor Interaction Defines a Novel Vasoprotective Mechanism

  2024cites this paper
• Co-activation of Mas and pGCA receptors suppresses endothelin-1-induced endothelial dysfunction via nitric oxide/cGMP system.

  2024cites this paper
• Angiotensin-Converting Enzyme 2 (ACE2) Signaling in Pulmonary Arterial Hypertension: Underpinning Mechanisms and Potential Targeting Strategies

  2023cites this paper
• Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats

  2023cites this paper
• Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters

  2022cites this paper
• Novel and emerging therapies in pulmonary arterial hypertension

  2022cites this paper
• Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19

  2021cites this paper
• Neurohormonal modulation in pulmonary arterial hypertension

  2021cites this paper
• Metformin prevents the development of monocrotaline-induced pulmonary hypertension by decreasing serum levels of big endothelin-1

  2020cites this paper
• Reversal of Hypoxic Pulmonary Hypertension by Hypoxia-Inducible Overexpression of Angiotensin-(1-7) in Pulmonary Endothelial Cells

  2020cites this paper
• Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost

  2020cites this paper
• Biosynthesis of lanthionine-constrained agonists of G protein-coupled receptors

  2020cites this paper
• Synergism between Angiotensin receptors ligands: Role of Angiotensin‐(1‐7) in modulating AT2R agonist response on nitric oxide in kidney cells

  2020cites this paper
• LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study.

  2020cites this paper
• Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19

  2020cites this paper
• Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges

  2020cites this paper
• Counter-regulatory renin–angiotensin system in cardiovascular disease

  2019cites this paper
• Efficacy of lanthionine‐stabilized angiotensin‐(1–7) in type I and type II diabetes mouse models

  2019cites this paper
• Pulmonary hypertension: Pathophysiology beyond the lung.

  2019cites this paper
• Investigational new drug enabling angiotensin oral-delivery studies to attenuate pulmonary hypertension.

  2019cites this paper
• Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases

  2018cites this paper
• Novel imaging approaches for small animal models of lung disease (2017 Grover Conference series)

  2018cites this paper
• ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad

  2018cites this paper
• A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension

  2018cites this paper
• Significance of angiotensin 1–7 coupling with MAS1 receptor and other GPCRs to the renin‐angiotensin system: IUPHAR Review 22

  2017cites this paper
• The vasoprotective axes of the renin‐angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases

  2017cites this paper
• The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7)

  2017cites this paper
• Search for an animal model to investigate selective pulmonary vasodilation

  2017cites this paper
• Inhibition of MLCK attenuates pulmonary artery hypertension

  2016cites this paper